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+ MODEL1. Introduction
Several decades ago, it was almost impossible to even
dream about the progress that has occurred in the diagnosis
and management of coronary atherosclerosis.1,2 Informa-
tion available related to coronary atherosclerosis in the
late fifties and early sixties were in its infancy. In 1768, Dr.
Heberden described extremely well the clinical picture of
angina pectoris at the Royal College of Physicians, however,
the cause of chest pain was unknown at the time.3 In 1912,
Dr. Herrick presented for the first time at the Association of
American Physicians in Chicago that an occlusion of a cor-
onary artery could produce an acute myocardial infarction
and not only death, which was the concept at that time.4 In
the middle of the last century, patients with an acute
myocardial infarction had to stay on bed rest for almost
forty days. At that time, Samuel Levine in Boston intro-
duced a revolutionary concept that a patient with an acute
myocardial infarction could sit in a chair.2 In the mid
1950’s, the president of the United States of America,
Dwight D Eisenhower, had an acute myocardial infarction in
Colorado and was forced to stay there for several weeks.2
Obviously, our approach to patients with acute myocar-
dial infarction is quite different today. The underlying pa-
thology of coronary atherosclerosis can be defined with a
great degree of accuracy in the cardiac catheterization
laboratory. This diagnosis was difficult to achieve even at
autopsy 60 years ago. Moreover, the development of
percutaneous coronary interventions has allowed the
revascularization of almost all coronary artery stenoses,
including total occlusions, in patients with stable disease
and/or acute coronary syndromes. These remarkable
achievements have allowed clinicians to take better care of
their patients and physicians/scientists to better under-
stand the underlying pathophysiologic mechanisms of the
disease. The discoveries related to the basic pathophysio-
logic mechanisms of atherosclerosis will help win the war
against coronary atherosclerosis, which in turn will diminish
or eliminate the role of interventional cardiology in this
disease.5e7 The focus of this paper will be to emphasize
several of the remarkable achievements interventional
cardiology has had on the underlying pathophysiologic
mechanisms of atherosclerosis. The authors, who are both
cardiologists and physicians/scientists with a special in-
terest in translational research, will also make certain
projections for the future based on current available
information.
2. Correlation of Clinical Picture with
Underlying Pathology and Pathophysiology
Prior to the introduction of coronary arteriography in
clinical practice, it was impossible to correlate the clinical
picture in vivo with the underlying coronary pathology. Dr
Mason Sones in Cleveland Clinic in October 30, 1958,
“accidentally” did a selective injection into the right
coronary artery. To his surprise, the patient did not have
any long-lasting serious issues after the injection. This was
the beginning of a long journey that among others provided
an in vivo correlation between the clinical picture of cor-
onary atherosclerosis with the underlying pathology.8 APlease cite this article in press as: Boudoulas KD, et al., The Role of In
Related to Coronary Atherosclerosis: “Thinking outside the box”, H
j.hjc.2016.10.002few years later, a group of patients with chest pain and
normal coronary arteries, the so-called “syndrome X”, was
described. Thus, it became obvious that not all chest pains
are related to obstructive coronary artery disease.1
Several decades later, several investigators reported that
mild to moderate coronary artery stenosis is responsible
for most myocardial infarctions9,10; this concept was
against the conventional wisdom of the time. These ob-
servations challenged the concept that the diagnosis of
coronary atherosclerosis could be based on stress-induced
ischemia. Ischemia cannot be induced when the stenosis is
less than 70% and thus, a stenosis that may produce a
myocardial infarction or sudden cardiac death in certain
instances cannot be diagnosed prior to a catastrophic
event.1 This information has stimulated the development
of newer diagnostic techniques such as computed tomog-
raphy, fractional flow reserve, and others, for the diag-
nosis of anatomic and physiologic significant coronary
artery stenoses.1,11e14 Although it was known that coro-
nary artery bypass surgery may damage nerves also
relieving chest pain and the incidence of angina, it was
coronary angioplasty that directly demonstrated the as-
sociation of chest pain with coronary artery stenosis when
Andreas Gruenzing performed a coronary angioplasty in a
patient with a critical left anterior coronary artery stenosis
in September 26, 1977.15 A decade later, Dr. Sigwart
showed that placement of a stent after angioplasty
decreased the incidence of restenosis. Other investigators
later introduced the idea of covered stents and drug
eluting stents. The introduction of stents, which may
thrombosis, has stimulated research related to thrombosis
and antithrombotic therapy.1,16
3. Thrombus Formation is Responsible for ST-
Elevation Myocardial Infarction
Another major contribution of interventional cardiology
was the concept that thrombus was almost always present
in patients with a ST-elevation myocardial infarction
(STEMI). Although pathologists earlier believed that
thrombosis was responsible for a STEMI,17 a prominent pa-
thologists in the 1970’s thought that thrombus formation
within the coronary artery in patients with a STEMI was a
post-mortem phenomena.18 Obviously, this concept had a
significant negative impact in the treatment of patients
with an acute myocardial infarction for a substantial period
of time. It was Dr. Dewood in 1980, almost a decade later,
which proved in vivo that this concept was inaccurate.19 He
and his colleagues performed a coronary arteriography in
patients with STEMI and demonstrated that within the first
hours after the onset of chest pain thrombus was present in
almost in all patients; 16 to 24 hours later, thrombus was
seen only in the minority of these patients. It should be
mentioned that coronary arteriography was absolutely
contraindicated in patients with acute myocardial infarc-
tion in 1980. Immediately after this information, other in-
vestigators demonstrated that intracoronary injection of
streptokinase produced dissolution of thrombus that
resulted in a decreased in the size of myocardial necrosis.20
These studies had a significant impact in our understanding
of the pathogenesis of acute myocardial infarction andterventional Cardiology to Our Understanding of Basic Mechanisms
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lesion decreased infarct size and preserved left ventricular
function. This was the beginning of a new era where
intravenous thrombolytic therapy and primary angioplasty
were introduced for the management of patients with
STEMI.21,22 These findings stimulated research in the area of
thrombosis and antithrombotic therapy, and contributed to
a better understanding of the role of thrombosis in coronary
atherosclerosis.23 Further, the analysis of material extrac-
ted from obstructed coronary arteries has provided new
insights into the atherothrombotic process in coronary
atherosclerosis.24
4. Contributions to Our Understanding of the
Definition and Evolution of Atherosclerotic
Plaque in Vivo
Current technology such as intravascular ultrasound (IVUS),
optical coherence tomography (OCT), and virtual histology
has allowed the structural analysis of the atherosclerotic
plaque including the precise definition of the thickness of
the cap covering the atherosclerotic plaque in vivo. In
addition, the vasa-vasorum (neo-vessel formation in
atherosclerotic plaques) can also be analyzed.25e27
Ruptured plaques in patients with an acute coronary syn-
drome also can be seen in vivo.28,29
Dr. Stefanadis introduced the thermographic catheter in
clinical practice that allowed the measurement of tem-
perature in atherosclerotic plaques and thus, define the
inflammatory process in vivo. Studies demonstrated that
the temperature in the culprit plaque in patients with an
acute coronary syndrome was higher compared to stable
atherosclerotic plaques (“fever” of the atherosclerotic
plaque). It was also shown that the temperature in the
coronary sinus in patients with coronary artery disease was
higher compared to patients with normal coronary arteries,
an indication that a diffuse inflammatory process was pre-
sent in the arterial tree in patients with coronary athero-
sclerosis.30,31 It is well known that inflammatory indices in
the systemic circulation (i.e., C-reactive protein or CRP)
may be high in patients with coronary atherosclerosis.5,32,33
Using the thermographic technique, it was shown that most
of the time there was a direct agreement present between
atherosclerotic plaque temperature and systemic inflam-
matory indices.30
Initial small in vivo studies using coronary arteriography
demonstrated that aggressive cholesterol reduction resul-
ted in mild regression of atherosclerotic plaques, stabili-
zation of plaques, and importantly in a dramatic reduction
in cardiovascular events.34 Later, several other studies with
a larger number of patients showed similar results. IVUS has
shown that atherosclerotic plaques can regress after
aggressive cholesterol reduction.25 It also was shown with
VIRTUAL histology that the absence of fibroatheroma in an
atherosclerotic plaque was a strong predictor of plaque
stability.27 These studies have contributed significantly to
our understanding of the evolution of stable and unstable
atherosclerotic plaques in vivo. It has been shown that
unstable plaques may be stabilized to a varying degree and
that stable plaques may become unstable. Further, these
studies have allowed an understanding that in a patientPlease cite this article in press as: Boudoulas KD, et al., The Role of In
Related to Coronary Atherosclerosis: “Thinking outside the box”, He
j.hjc.2016.10.002several unstable plaques may be present at the same time
and that neo-vessel formation and an inflammatory process
are present in unstable atherosclerotic plaques.1,27,31
5. Contributions of Interventional Cardiology
to Our Understanding of the Importance of Left
Ventricular Systolic Function in Coronary
Atherosclerosis
Until the early 1980’s, it was thought that the number of
coronary arteries diseased was the strongest prognostic in-
dicator in patients with coronary atherosclerosis. Obviously,
it was impossible to define the prognostic significance of left
ventricular systolic function in relation to the number of
diseased vessels without the emergence of coronary arteri-
ography. Our group initially demonstrated in a relatively
small number of patients that left ventricular systolic
function was a stronger prognostic indicator compared to
the number of diseased coronary arteries. It was also found
that coronary artery bypass surgery and/or therapy with
beta-blockers increased survival only in patients with left
ventricular systolic dysfunction.35,36 Today there are multi-
ple studies to support this notion.37e39 Thrombolytic therapy
and primary angioplasty increase survival in patients with an
acute myocardial infarction simply because they preserve
left ventricular function. Cell based therapy was introduced
to improve left ventricular systolic function. Needless to say
that the contribution of interventional cardiology in this
area has also been of great importance.1,40
6. Future Considerations
“Time present and time past. Are both perhaps present
in time future.
And time future contained in time past” e T. S Eliot
Despite all this impressive technology of time present we
should not lose sight with reality and be aware that coro-
nary atherosclerosis cannot be cured today. In the early
1970’s, Dr. Lewis Thomas proposed a concept that he called
halfway technology.41 Halfway technology, which substan-
tially increases medical cost, cannot cure diseases; how-
ever, halfway technology does provide new insight into
pathophysiology, gives a better understanding of the basic
mechanisms of diseases, and eventually results in the pre-
vention and cure of diseases of time present, as it was the
case with diseases of time past. This is the ultimate goal of
medicine. For example, several infectious diseases such as
rheumatic fever, rheumatic valve disease, syphilis with all
of its cardiovascular involvements, poliomyelitis, and
peptic ulcer disease are rarely seen today in developed
countries. Halfway technology that was used to treat peptic
ulcer disease (i.e., extensive surgery) in the past has been
replaced with simple medical therapy that almost has
eliminated the disease today. Halfway technology of time
present (i.e., bypass surgery and/or percutaneous in-
terventions) is used to treat, but not cure coronary
atherosclerosis; this technology, however, will help us to
better understand the basic mechanisms of atherosclerosis
and eventually provide a cure and/or to prevent the disease
in time future.42e45terventional Cardiology to Our Understanding of Basic Mechanisms
llenic Journal of Cardiology (2016), http://dx.doi.org/10.1016/
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+ MODEL7. Concluding Remarks
The contributions of interventional cardiology to our un-
derstanding of coronary atherosclerosis are of great
importance.1,2,46 Interventional cardiology has allowed an
in vivo correlation between the clinical picture of coronary
atherosclerosis with the underlying pathology. Because of
interventional cardiology the causes of chest pain with non-
obstructive coronary arteries has been defined. Interven-
tional cardiology demonstrated that a plaque producing a
small degree of stenosis may lead to an acute coronary
syndrome. This important information challenged the
concept that the diagnosis of coronary artery disease can
be based on stress induced ischemia, because in many in-
stances it may be too late (i.e., after an acute myocardial
infarction or sudden cardiac death). Interventional cardi-
ology has contributed significantly to our understanding of
the evolution of stable and unstable atherosclerotic pla-
ques in vivo. In addition, that a patient may have several
unstable plaques present at the same time and that neo-
vessel formation and an inflammatory process are present
in unstable atherosclerotic plaques. Interventional cardi-
ology demonstrated for the first time in vivo that thrombus
formation was present in patients with a STEMI. These
findings have stimulated research related to thrombosis and
antithrombotic therapy. Because of the interventional
cardiology, it was determined that left ventricular systolic
function is a stronger prognostic indicator compared to the
number of diseased coronary arteries. Interventional car-
diology contributed to our understanding that revasculari-
zation of an occluded vessel in an acute myocardial
infarction improves left ventricular function and increases
survival. The discoveries by interventional cardiology
related to the underlying pathophysiology of coronary
atherosclerosis will help cure and/or prevent coronary
atherosclerosis in the future, and in turn diminish the role
of interventional cardiology in this disease. It should be
mentioned, however, that patient oriented research and
translational research performed by a “thinking” inter-
ventional and non-interventional cardiologist/scientist, and
not disease oriented research (i.e., mega trials), will solve
this problem.Disclosure and Conflict of Interest
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